Innsbruck - Tyrolean Working Group of Experimental Oncology Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2010
NCT01166035
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2010

Timeline

NOW
  • Now

Alternative names

Innsbruck - Tyrolean Working Group of Experimental Oncology (TEXO)

Active Ingredients

Drugs in Phase 2 Trials (2)

cetuximab (erbitux) (1 trial)

lenalidomide (revlimid) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 2